Anti-IgE (Omalizumab) in the treatment of uncontrolled severe asthmatic patients

被引：0
|
作者：
Hinojosa, M. [1 ]
Huertas, B. [1 ]
Gonzalez-Cervera, J. [1 ]
Diez-Gomez, M. [1 ]
Sanchez-Cano, M. [1 ]
Pacheco, A. [1 ]
机构：
[1] Hosp Ramon & Cajal, E-28034 Madrid, Spain
来源：
ALLERGY | 2007年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：209 / 209
页数：1
相关论文
共 50 条
  • [41] Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis
    Chervinsky, P
    Casale, T
    Townley, R
    Tripathy, I
    Hedgecock, S
    Fowler-Taylor, A
    Shen, H
    Fox, H
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2003, 91 (02) : 160 - 167
  • [42] Clinical efficacy of anti-IgE therapy in adult patients with atopic severe uncontrolled asthma in real practice
    Ignatova, G. L.
    Blinova, E., V
    Zakharova, I. A.
    Kochetkova, S. A.
    Revel-Muroz, N. P.
    ALLERGY, 2018, 73 : 671 - 671
  • [43] Pilot study of omalizumab (anti-IgE) in eosinophilic gastroenteritis
    Foroughi, S
    Mannon, PJ
    Bernardino, LB
    Foster, B
    Scott, LM
    Metcalfe, DD
    Prussin, C
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (02) : S304 - S304
  • [44] Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in CF With Anti-IgE Antibody (Omalizumab)
    Kanu, Adaobi
    Patel, Kalpana
    PEDIATRIC PULMONOLOGY, 2008, 43 (12) : 1249 - 1251
  • [45] The anti-IgE antibody omalizumab as a probe to investigate the role of IgE in pathology
    Mauro, M.
    Incorvaia, C.
    Formigoni, C.
    Elia, R.
    Russello, M.
    Pellegrino, D.
    PANMINERVA MEDICA, 2012, 54 (04) : 305 - 311
  • [46] Omalizumab, a novel anti-IgE therapy in allergic disorders
    Babu, KS
    Arshad, SH
    Holgate, ST
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2001, 1 (06) : 1049 - 1058
  • [47] Current and future applications of the anti-IgE antibody omalizumab
    Incorvaia, Cristoforo
    Mauro, Marina
    Riario-Sforza, Gian Galeazzo
    Frati, Franco
    Tarantini, Francesco
    Caserini, Maurizio
    BIOLOGICS-TARGETS & THERAPY, 2008, 2 (01): : 67 - 73
  • [48] Safety of anti-IgE therapy with omalizumab in allergic patients at risk of geohelminth infection
    Cooper, PJ
    Lima, F
    Sarinho, EC
    Ayre, G
    Martin, C
    Fox, H
    Cruz, AA
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (02) : S9 - S9
  • [49] Effect of omalizumab treatment on allergic comorbidities in patients with severe allergic asthma - real life experience from Czech Anti-IgE Registry
    Hutyrova, Beata
    Bystron, Jaromir
    Chlumsky, Jan
    Kindlova, Dagmar
    Klosova, Jana
    Krcmova, Irena
    Novotna, Bronislava
    Panzner, Petr
    Pohunek, Petr
    Ruzickova-Kirchnerova, Olga
    Sedlak, Vratislav
    Terl, Milan
    Vanik, Petr
    Vasakova, Martina
    Vernerova, Eva
    Zatloukal, Jaromir
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [50] EFFICACY OF OMALIZUMAB, AN ANTI-IGE RECOMBINANT, HUMANIZED, MONOCLONAL ANTIBODY, FOR THE TREATMENT OF SEVERE CHRONIC IDIOPATHIC URTICARIA PATIENTS NOT CONTROLLED ON ORAL ANTIHISTAMINES
    Nsouli, S. M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2013, 111 (05) : A117 - A117
12345